Sibelium: Targeted Migraine Prophylaxis for Lasting Relief
| Product dosage: 10 mg | |||
|---|---|---|---|
| Package (num) | Per tab | Price | Buy |
| 30 | $1.37 | $41.16 (0%) | 🛒 Add to cart |
| 60 | $0.75 | $82.33 $45.18 (45%) | 🛒 Add to cart |
| 90 | $0.56 | $123.49 $50.20 (59%) | 🛒 Add to cart |
| 120 | $0.44 | $164.66 $53.21 (68%) | 🛒 Add to cart |
| 180 | $0.31
Best per tab | $246.99 $55.22 (78%) | 🛒 Add to cart |
| Product dosage: 5 mg | |||
|---|---|---|---|
| Package (num) | Per tab | Price | Buy |
| 30 | $1.20 | $36.14 (0%) | 🛒 Add to cart |
| 60 | $0.69 | $72.29 $41.16 (43%) | 🛒 Add to cart |
| 90 | $0.48 | $108.43 $43.17 (60%) | 🛒 Add to cart |
| 120 | $0.39 | $144.58 $47.19 (67%) | 🛒 Add to cart |
| 180 | $0.27
Best per tab | $216.86 $49.20 (77%) | 🛒 Add to cart |
Synonyms | |||
Sibelium, with the active ingredient flunarizine dihydrochloride, is a selective calcium channel blocker specifically indicated for the prophylaxis of migraine. It represents a cornerstone in preventive neurological therapy, designed to reduce the frequency, severity, and duration of migraine attacks in suitable patients. By modulating vascular tone and neuronal excitability, it addresses the underlying pathophysiological mechanisms of migraine, offering a structured approach to chronic management. This expert guide details its pharmacological profile, clinical application, and essential safety information for healthcare professionals and informed patients.
Features
- Active Ingredient: Flunarizine dihydrochloride
- Pharmacological Class: Selective calcium entry blocker with antihistaminic and dopaminergic properties
- Standard Tablet Strength: 5 mg and 10 mg
- Mechanism of Action: Inhibits calcium influx into vascular smooth muscle and neurons; reduces vestibular excitability
- Bioavailability: High oral bioavailability with extensive tissue distribution
- Half-life: Approximately 18 days, allowing for once-daily dosing
- Metabolism: Hepatic, via cytochrome P450 system
- Excretion: Primarily fecal, with some renal elimination
Benefits
- Significantly reduces the frequency and intensity of migraine attacks
- Decreases the need for acute migraine abortive medications
- Improves overall quality of life by enabling better daily function and planning
- Offers convenient once-daily dosing due to long half-life, enhancing adherence
- Provides prophylactic benefits for vestibular vertigo in certain patient profiles
- Demonstrates a favorable benefit-risk profile in long-term migraine management
Common use
Sibelium (flunarizine) is primarily prescribed for the prophylactic treatment of migraine. It is indicated for patients experiencing frequent or severe migraine attacks (typically defined as more than 2-3 attacks per month) that significantly impair quality of life or are refractory to acute treatments. It is also used off-label in some regions for management of vertigo of vestibular origin. It is not intended for the acute treatment of a migraine attack once it has begun. Use is generally reserved for adults and, in some cases, adolescents under strict neurological supervision.
Dosage and direction
The standard initial adult dosage for migraine prophylaxis is 10 mg once daily, taken in the evening to mitigate potential drowsiness. For elderly patients, or those with low body weight or heightened sensitivity, a starting dose of 5 mg daily may be recommended. Treatment should be initiated under medical supervision. A clinical response is typically evaluated after 1-2 months of continuous therapy. If effective and well-tolerated, treatment may be continued for several months. The dosage should be tapered gradually upon discontinuation to avoid rebound effects. The tablets should be swallowed whole with water, with or without food.
Precautions
Patients should be monitored for the emergence of drowsiness, which may impair the ability to drive or operate machinery, particularly at the start of therapy. Weight gain has been reported and should be monitored through periodic checks. Caution is advised in patients with a history of depressive illness or pre-existing extrapyramidal symptoms, as flunarizine may exacerbate these conditions. Liver function tests may be considered during prolonged therapy. Use during pregnancy should only be considered if the potential benefit justifies the potential risk to the fetus. It is not recommended during breastfeeding.
Contraindications
Sibelium is contraindicated in patients with known hypersensitivity to flunarizine dihydrochloride or any of the excipients in the formulation. Its use is also contraindicated in patients with a history of depressive illness, especially with suicidal ideation, or pre-existing Parkinson’s disease and other extrapyramidal disorders. It should not be used in patients with severe liver impairment.
Possible side effect
Common side effects may include drowsiness, weight gain, and fatigue. Other frequently reported effects are dry mouth, nausea, and gastrointestinal discomfort. Less commonly, patients may experience muscle aches, hypotension, or bradycardia. Rare but serious side effects include depression, extrapyramidal symptoms (such as tremor or akathisia), and galactorrhea. Any emergence of mood changes or motor disturbances should be reported to a physician immediately.
Drug interaction
Flunarizine is metabolized by the cytochrome P450 system (CYP2D6). Concomitant use with other CNS depressants (e.g., alcohol, benzodiazepines, opioids) may potentiate sedative effects. Caution is warranted with drugs that prolong the QT interval. It may potentiate the effects of antihypertensive agents. Concurrent administration with other dopamine antagonists or drugs known to cause extrapyramidal symptoms should be avoided. Strong inhibitors of CYP2D6 may increase flunarizine plasma concentrations.
Missed dose
If a dose is missed, it should be taken as soon as remembered on the same day. If it is nearly time for the next scheduled dose, the missed dose should be skipped. Do not double the dose to make up for a missed one. Maintaining a consistent dosing schedule is important for stable plasma levels.
Overdose
Symptoms of overdose are primarily an extension of its pharmacological effects and may include severe drowsiness, sedation, hypotension, bradycardia, and agitation. In case of suspected overdose, seek immediate medical attention. Gastric lavage may be considered if ingestion was recent. Treatment is supportive and symptomatic, with close monitoring of vital signs and cardiac function. There is no specific antidote.
Storage
Store at room temperature (15-25°C / 59-77°F) in a dry place, protected from light and moisture. Keep the bottle tightly closed. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging.
Disclaimer
This information is for educational and professional reference purposes only and is not a substitute for direct medical advice from a qualified healthcare professional. Always consult a physician for diagnosis, treatment decisions, and personalized dosage recommendations. The prescribing information provided here is a summary and may not include all possible information, uses, directions, precautions, or interactions.
Reviews
“After six months on Sibelium, my migraine days have been cut by over 70%. The initial drowsiness subsided after a few weeks. It has been a life-changing intervention for my chronic migraine.” – Patient M, 42 “A reliable option for prophylaxis in patients who have failed first-line beta-blockers. The long half-life is a significant advantage for adherence. Monitoring for mood and weight changes is essential.” – Neurologist, 15 years experience “Effective for reducing attack frequency, but the side effect of weight gain was a significant issue for me, leading to a discussion about alternative options with my doctor.” – Patient T, 35 “Flunarizine remains a valuable tool in our armamentarium, particularly for patients with comorbid vertigo. Its dual action is unique among preventive treatments.” – Headache Specialist